English
Human IGFBP-3 Recombinant
Human IGFBP-3 Recombinant
Artikelnummer
BPS90165-A
Verpackungseinheit
5 µg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Background: IGFBPs are synthesized in the liver and are produced also by various tumor cell lines and cell types. IGFBPs are high affinity binding proteins for IGF. The major fraction of both types of IGF circulating in the blood are bound non-covalently to these carrier proteins. IGF binding proteins modulate IGF activities by increasing their plasma half lives and by inhibiting or promoting the interactions of IGF with receptors on certain target cells. In addition these binding proteins provide a reservoir for IGF in pericellular spaces. Some IGFBPs also have stimulating effects in vitro and some may inhibit the growth of cells. IGFBP1 is found predominantly in the placenta and the amniotic fluid. The predominant sites of IGFBP1 transcription in the human fetal kidney are those with most active differentiation. Elevated serum levels have been observed in patients with Laron-type dwarfism and Growth hormone deficiency. High serum levels of IGFBP1 are found in newborns and it has been suggested that this could be important in protecting them from hypoglycemia.
Biological Activity: The ED50 was determined by the ability to inhibit IGF-I induced proliferation of MCF-7 and was found to be ≤ 0.5 µg/ml.
Description: Recombinant IGFBP-3 is a disulfide-linked monomer protein consisting of 264 amino acid residues, migrates as an approximately 28 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human IGFBP-3 mature chain was expressed in E. coli.
Endotoxin Level: <0.1 ng/µg (1 EU/µg), using the LAL gel clot method.
Format: lyophilized protein
Formulation: Lyophilized from 0.2 µm filtered PBS, pH 7.0.
Genbank: P17936
Purity: ≥95% by SDS-PAGE and HPLC
Reconstitution: Reconstitute at 0.1-1.0 mg/ml in distilled water. This solution can then be diluted into other buffers. To maximize product collection from vial surface, vortex briefly and then spin down to recollect the liquid.
Storage Stability: The lyophilized protein is stable for at least 2 years from date of receipt when stored at -20°C. Upon reconstitution, store in working aliquots at +4°C for up to one month, or at -20°C for up to six months, in the presence of a carrier protein. Avoid repeated freeze/thaw cycles.
Uniprot: P17936
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. McCarthy, K., et al. Anticancer Research October 2009 vol. 29 no. 10 3785-3790.
2. Volzke, H., et al. Eur J Endocrinol November 1, 2009 161 705-713.
3. Paharkova-Vatchkova, V. And Lee, K-W. Endocr Relat Cancer June 1, 2010 17 293-302.
Background: IGFBPs are synthesized in the liver and are produced also by various tumor cell lines and cell types. IGFBPs are high affinity binding proteins for IGF. The major fraction of both types of IGF circulating in the blood are bound non-covalently to these carrier proteins. IGF binding proteins modulate IGF activities by increasing their plasma half lives and by inhibiting or promoting the interactions of IGF with receptors on certain target cells. In addition these binding proteins provide a reservoir for IGF in pericellular spaces. Some IGFBPs also have stimulating effects in vitro and some may inhibit the growth of cells. IGFBP1 is found predominantly in the placenta and the amniotic fluid. The predominant sites of IGFBP1 transcription in the human fetal kidney are those with most active differentiation. Elevated serum levels have been observed in patients with Laron-type dwarfism and Growth hormone deficiency. High serum levels of IGFBP1 are found in newborns and it has been suggested that this could be important in protecting them from hypoglycemia.
Biological Activity: The ED50 was determined by the ability to inhibit IGF-I induced proliferation of MCF-7 and was found to be ≤ 0.5 µg/ml.
Description: Recombinant IGFBP-3 is a disulfide-linked monomer protein consisting of 264 amino acid residues, migrates as an approximately 28 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human IGFBP-3 mature chain was expressed in E. coli.
Endotoxin Level: <0.1 ng/µg (1 EU/µg), using the LAL gel clot method.
Format: lyophilized protein
Formulation: Lyophilized from 0.2 µm filtered PBS, pH 7.0.
Genbank: P17936
Purity: ≥95% by SDS-PAGE and HPLC
Reconstitution: Reconstitute at 0.1-1.0 mg/ml in distilled water. This solution can then be diluted into other buffers. To maximize product collection from vial surface, vortex briefly and then spin down to recollect the liquid.
Storage Stability: The lyophilized protein is stable for at least 2 years from date of receipt when stored at -20°C. Upon reconstitution, store in working aliquots at +4°C for up to one month, or at -20°C for up to six months, in the presence of a carrier protein. Avoid repeated freeze/thaw cycles.
Uniprot: P17936
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. McCarthy, K., et al. Anticancer Research October 2009 vol. 29 no. 10 3785-3790.
2. Volzke, H., et al. Eur J Endocrinol November 1, 2009 161 705-713.
3. Paharkova-Vatchkova, V. And Lee, K-W. Endocr Relat Cancer June 1, 2010 17 293-302.
| Artikelnummer | BPS90165-A |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 90165-A |
| Green Labware | Nein |
| Verpackungseinheit | 5 µg |
| Mengeneinheit | STK |
| Produktinformation (PDF) |
|
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
